Regeneron Pharmaceuticals, Inc. — Q1 2014 Form 10-Q Summary
Business context and reporting period
Regeneron is an integrated biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines. The filing covers the three months ended March 31, 2014, with comparative results for the three months ended March 31, 2013. Marketed products were EYLEA, ZALTRAP, and ARCALYST. EYLEA remained the principal commercial driver.
Key financial metrics
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Total revenue | $625.7 million | $439.7 million | +42.3% |
| Net product sales | $362.4 million | $318.7 million | +13.7% |
| Sanofi collaboration revenue | $130.5 million | $99.3 million | +31.4% |
| Bayer HealthCare collaboration revenue | $125.3 million | $14.9 million | Significant increase |
| Operating income | $185.9 million | $153.1 million | +21.5% |
| Operating margin | 29.7% | 34.8% | Down 5.1 percentage points |
| Net income | $65.4 million | $98.9 million | -33.8% |
| Diluted EPS | $0.58 | $0.90 | -35.6% |
| Effective tax rate | 62.7% | 30.3% | Up 32.4 percentage points |
| Operating cash flow | $53.5 million | $86.2 million | -37.9% |
| Capital expenditures | $64.8 million | $21.2 million | +205.7% |
EYLEA U.S. net product sales increased to $359.0 million from $313.9 million, primarily from higher volume. ARCALYST sales declined to $3.4 million from $4.8 million. Bayer recorded $218.1 million of EYLEA sales outside the United States, compared with $62.0 million in the prior-year quarter; Regeneron recorded its share of related profits as collaboration revenue.
Revenue benefited from two $15.0 million EYLEA sales milestones from Bayer and increased reimbursement and cost-sharing activity. Bayer also recognized collaboration revenue related to a $25.5 million PDGFR-beta upfront payment and two $2.5 million milestones over the related performance period.
Research and development expense rose to $287.4 million from $180.3 million, driven by higher clinical activity, headcount, manufacturing, and collaboration cost-sharing. Selling, general, and administrative expense increased to $108.9 million from $77.3 million. Non-cash compensation expense was $81.4 million, compared with $53.0 million.
Cash, cash equivalents, and marketable securities totaled approximately $1.18 billion at March 31, 2014, including $461.9 million of cash and cash equivalents and $721.0 million of marketable securities. Total assets were $3.26 billion and total stockholders' equity was $2.21 billion. Debt included $400.0 million principal amount of 1.875% convertible senior notes due October 1, 2016, with a carrying value of $326.7 million.
Material changes versus the prior comparable period
- Revenue growth was led by international EYLEA commercialization and related Bayer collaboration economics, including $30.0 million of sales milestones.
- Operating income increased, but operating margin contracted because expenses grew faster than revenue.
- Net income declined despite higher operating income, primarily because the effective tax rate increased sharply. The tax rate was affected by expiration of the federal research tax credit, foreign losses, and New York tax legislation, which produced a 10.4 percentage-point adverse impact.
- Operating cash flow declined as accounts receivable, inventories, and prepaid assets increased. EYLEA trade receivables were approximately $800.2 million at quarter-end.
- Investing cash outflow increased to $236.2 million, including $64.8 million of capital expenditures and net purchases of marketable securities.
- R&D cost-sharing increased following the commencement of Regeneron's obligation to fund 20% of certain Sanofi Phase 3 costs. Regeneron recorded $23.8 million of antibody development expense related to alirocumab and sarilumab and paid two $5.0 million PDGF development milestones to Sanofi.
Guidance, outlook, commentary, and risks
Management expected capital expenditures of approximately $280 million to $350 million during the remainder of 2014, primarily for Rensselaer manufacturing expansion, Tarrytown facilities, equipment, and the proposed Limerick, Ireland facility. The Limerick acquisition remained subject to definitive agreements and permits.
Management stated that existing capital resources, anticipated EYLEA sales, and collaborator reimbursements were expected to fund operating needs for the foreseeable future. The company did not provide a clear consolidated revenue or earnings forecast in the filing.
Near-term development priorities included regulatory decisions for EYLEA in diabetic macular edema and macular edema following branch retinal vein occlusion, continued Phase 3 development of alirocumab and sarilumab, advancement of dupilumab, and development of REGN2176-3.
- The company was substantially dependent on EYLEA; U.S. EYLEA sales represented 57% of total revenue in Q1 2014.
- Revenue was concentrated among distributors; 79% of gross product revenue was recorded from Besse Medical, a subsidiary of AmerisourceBergen.
- Material risks included regulatory approval and safety uncertainty, reimbursement and pricing pressure, competition from Lucentis and off-label Avastin, manufacturing capacity and supply-chain constraints, and potential termination or underperformance of Sanofi or Bayer collaborations.
- Patent litigation involving the '287 and '018 patents was ongoing against Novo Nordisk, Merus, and Ablexis. The filing stated that the proceedings were at an early stage and that outcomes could not be predicted.
- Fasinumab remained on FDA clinical hold. The FDA also requested assessment of potential neurocognitive events in the alirocumab development program.
- In April 2014, holders surrendered $61.1 million principal amount of convertible notes for conversion, with settlement expected in Q2 2014 through a combination of cash and shares.
- In May 2014, Regeneron entered a gene-therapy research collaboration with Avalanche Biotechnologies involving $8.0 million of upfront and prepaid research payments, a $5.0 million equity investment, potential milestones, and royalties.
Most important facts for an investor to verify
- Whether EYLEA U.S. volume growth and international sales momentum can offset increasing R&D, manufacturing, commercialization, and collaboration costs.
- The sustainability of profitability after excluding one-time collaboration milestones and considering the elevated tax rate in Q1 2014.
- Collection of the large EYLEA-related receivables and the effect of shortened customer payment terms on future operating cash flow.
- The timing and outcomes of EYLEA regulatory decisions for DME and BRVO, and the continued safety and efficacy profile of EYLEA.
- The progress, regulatory risk, and eventual commercial potential of alirocumab, sarilumab, dupilumab, and other pipeline candidates.
- The effect of planned 2014 capital expenditures and manufacturing expansion on liquidity and execution risk.
- The financial impact of the convertible-note conversion, collaborator reimbursement obligations, Genentech royalties, and pending patent litigation.